Literature DB >> 2179476

The treatment of recurrent brain metastases with stereotactic radiosurgery.

J S Loeffler1, H M Kooy, P Y Wen, H A Fine, C W Cheng, E G Mannarino, J S Tsai, E Alexander.   

Abstract

Between May 1986 and August 1989, we treated 18 patients with 21 recurrent or persistent brain metastases with stereotactic radiosurgery using a modified linear accelerator. To be eligible for radiosurgery, patients had to have a performance status of greater than or equal to 70% and have no evidence of (or stable) systemic disease. All but one patient had received prior radiotherapy, and were treated with stereotactic radiosurgery at the time of recurrence. Polar lesions were treated only if the patient had undergone and failed previous complete surgical resection (10 patients). Single doses of radiation (900 to 2,500 cGy) were delivered to limited volumes (less than 27 cm3) using a modified 6MV linear accelerator. The most common histology of the metastatic lesion was carcinoma of the lung (seven patients), followed by carcinoma of the breast (four patients), and melanoma (four patients). With median follow-up of 9 months (range, 1 to 39), all tumors have been controlled in the radiosurgery field. Two patients failed in the immediate margin of the treated volume and were subsequently treated with surgery and implantation of 125I to control the disease. Radiographic response was dramatic and rapid in the patients with adenocarcinoma, while slight reduction and stabilization occurred in those patients with melanoma, renal cell carcinoma, and sarcoma. The majority of patients improved neurologically following treatment, and were able to be withdrawn from corticosteroid therapy. Complications were limited and transient in nature and no cases of symptomatic radiation necrosis occurred in any patient despite previous exposure to radiotherapy. Stereotactic radiosurgery is an effective and relatively safe treatment for recurrent solitary metastases and is an appealing technique for the initial management of deep-seated lesions as a boost to whole brain radiotherapy.

Entities:  

Mesh:

Year:  1990        PMID: 2179476     DOI: 10.1200/JCO.1990.8.4.576

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  45 in total

1.  Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.

Authors:  Louis Burt Nabors; Jana Portnow; Mario Ammirati; Henry Brem; Paul Brown; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Jona Hattangadi-Gluth; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Paul L Moots; Maciej M Mrugala; Herbert B Newton; Jeffrey J Raizer; Lawrence Recht; Nicole Shonka; Dennis C Shrieve; Allen K Sills; Lode J Swinnen; David Tran; Nam Tran; Frank D Vrionis; Patrick Yung Wen; Nicole R McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

2.  Unresectable Hepatocellular Carcinoma Due to Portal Venous Thrombosis: Focal Stereotactic Body Radiation Therapy Can Promote Resectability.

Authors:  Andrew Y Lee; Tianming Wu; Michael W Vannier; Giuliano Testa; Stanley L Liauw
Journal:  J Gastrointest Cancer       Date:  2012-09

3.  Central nervous system cancers.

Authors:  Louis Burt Nabors; Mario Ammirati; Philip J Bierman; Henry Brem; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Moshe H Maor; Paul L Moots; Tara Morrison; Maciej M Mrugala; Herbert B Newton; Jana Portnow; Jeffrey J Raizer; Lawrence Recht; Dennis C Shrieve; Allen K Sills; David Tran; Nam Tran; Frank D Vrionis; Patrick Y Wen; Nicole McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

Review 4.  Radiotherapy and chemotherapy of brain metastases.

Authors:  R Soffietti; A Costanza; E Laguzzi; M Nobile; R Rudà
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 5.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

6.  Cyberknife stereotactic radiosurgery for the re-irradiation of brain lesions: a single-centre experience.

Authors:  Daniela Greto; Lorenzo Livi; Pierluigi Bonomo; Laura Masi; Beatrice Detti; Icro Meattini; Monica Mangoni; Raffaella Doro; Virginia Favuzza; Samantha Cipressi; Carmine Iermano; Ivano Bonucci; Mauro Loi; Gianpaolo Biti
Journal:  Radiol Med       Date:  2014-01-28       Impact factor: 3.469

7.  Radiosurgery for recurrent brain metastases after whole-brain radiotherapy : factors affecting radiation-induced neurological dysfunction.

Authors:  Ho-Shin Gwak; Hyung Jun Yoo; Sang-Min Youn; Dong Han Lee; Mi Sook Kim; Chang Hun Rhee
Journal:  J Korean Neurosurg Soc       Date:  2009-05-31

8.  Efficacy, safety and outcome of frameless image-guided robotic radiosurgery for brain metastases after whole brain radiotherapy.

Authors:  Laura-Nanna Lohkamp; Peter Vajkoczy; Volker Budach; Markus Kufeld
Journal:  J Neurooncol       Date:  2018-01-29       Impact factor: 4.130

Review 9.  Conventional fractionated radiation therapy vs. radiosurgery for selected benign intracranial lesions (arteriovenous malformations, pituitary adenomas, and acoustic neuromas).

Authors:  L B Marks
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

Review 10.  The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Mario Ammirati; Charles S Cobbs; Mark E Linskey; Nina A Paleologos; Timothy C Ryken; Stuart H Burri; Anthony L Asher; Jay S Loeffler; Paula D Robinson; David W Andrews; Laurie E Gaspar; Douglas Kondziolka; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Roy A Patchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.